Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands

Current Medical Research and Opinion

Volumn 24, Issue 1, 2008, Pages 51-61

  Hoogendoorn, Martine ^a   Welsing, Paco ^b   Rutten van Mölken, Maureen P M H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b PFIZER INC   (United States)

Author keywords

Cost effectiveness; Model; Smoking cessation; Varenicline

Indexed keywords

AMFEBUTAMONE; NORTRIPTYLINE; VARENICLINE;

ADULT; AGED; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; ECONOMIC ASPECT; FEMALE; HUMAN; LONG TERM CARE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; QUALITY OF LIFE; SMOKING CESSATION; STROKE;

EID: 38549170978     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X242917     Document Type: Article

References (63)

1. The European Tobacco Control Report 2007. World Health Organization, Regional Office for Europe, Copenhagen; 2007. www.euro.who.int/document/e89842. pdf [accessed June 27, 2007]
2. World Health Organization (WHO). Why is tobacco a public health priority? Available at: www.who.int/tobacco/health_priority/en/print.html [December, 2006]
3. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet 1997;349:1436-42
4. Piasecki TM. Relapse to smoking. Clin Psychol Rev 2006;26:196-215
5. Zhu S, Melcer T, Sun J, et al. Smoking cessation with and without assistance: a population-based analysis. Am J Prev Med 2000;18:305-11
6. Baillie AJ, Mattick RP, Hall W. Quitting smoking: estimation by meta-analysis of the rate of unaided smoking cessation. Aust J Public Health 1995;19:129-31
7. Silagy C, Lancaster T, Stead L, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004;3:CD000146
8. Hughes J, Stead L, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007;1:CD000031
9. Wagena EJ, Knipschild P, Zeegers MP. Should nortriptyline be used as a first-line aid to help smokers quit? Results from a systematic review and meta-analysis. Addiction 2005;100:317-26
10. Wagena EJ, Knipschild PG, Huibers MJ, et al. Efficacy of bupropion and nortriptyline for smoking cessation among people at risk of or with chronic obstructive pulmonary disease. Arch Intern Med 2005;165:2286-92
11. Kotz D, Wagena EJ, Wesseling G. Smoking cessation practices of Dutch general practitioners, cardiologists, and lung physicians. Respir Med 2007;101:568-73
12. Bolin K, Lindgren B, Willers S. The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden. Chest 2006;129:651-60
13. Hall SM, Lightwood JM, Humfleet GL, et al. Cost-effectiveness of bupropion, nortriptyline, and psychological intervention in smoking cessation. J Behav Health Serv Res 2005;32:381-92
14. Javitz HS, Swan GE, Zbikowski SM, et al. Cost-effectiveness of different combinations of bupropion SR dose and behavioral treatment for smoking cessation: a societal perspective. Am J Manag Care 2004;10:217-26
15. Stapleton JA, Lowin A, Russell MA. Prescription of transdermal nicotine patches for smoking cessation in general practice: evaluation of cost-effectiveness. Lancet 1999;354:210-5
16. Wasley MA, McNagny SE, Phillips VL, et al. The cost-effectiveness of the nicotine transdermal patch for smoking cessation. Prev Med 1997;26:264-70
17. Fiscella K, Franks P. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling. J Am Med Assoc 1996;275:1247-51
18. Oster G, Huse DM, Delea TE, et al. Cost-effectiveness of nicotine gum as an adjunct to physician's advice against cigarette smoking. J Am Med Assoc 1986;256:1315-8
19. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. J Am Med Assoc 2006;296:56-63
20. Wu P, Wilson K, Dimoulas P, et al. Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health 2006;6:300
21. O'Regan CP, Baker C, Marchant N. The cost-effectiveness of the novel prescription therapy varenicline in Scotland. Meeting of the Society for Research on Nicotine and Tobacco; 2006
22. Orme ME, Hogue SL, Kennedy LM, et al. Development of the health and economic consequences of smoking interactive model. Tob Control 2001;10:55-61
23. Thun MJ, Apicella LF, Henley SJ. Smoking vs other risk factors as the cause of smoking-attributable deaths: confounding in the courtroom. J Am Med Assoc 2000;284:706-12
24. Feenstra TL, van Genugten ML, Hoogenveen RT, et al. The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. Am J Respir Crit Care Med 2001;164:590-6
25. Statistics Netherlands. Voorburg/Heerlen; 2006
26. van Baal PH, Hoeymans N, Hoogenveen RT, et al. Disability weights for comorbidity and their influence on health-adjusted life expectancy. Popul Health Metr 2006;4:1
27. STIVORO. Roken, de harde feiten: Volwassen 2004. [Smoking facts, adults 2004]. Den Haag: STIVORO; 2004
28. Poos MJJC. COPD: prevalentie, incidentie, ziekenhuisopnamen en sterfte naar leeftijd en geslacht. [COPD: prevalence, incidence, hospitalizations and mortality by age and gender]. In: Volksgezondheid Toekomst Verkenning, Nationaal Kompas Volksgezondheid. Bilthoven: RIVM; 2006
29. Stouthard MEA, Essink-Bot ML, Bonsel GJ. Disability weights for diseases: a modified protocol and results for a Western European region. Eur J Public Health 2000;10:24-30
30. Feenstra TL, Hamberg-van Reenen HH, Hoogenveen RT, et al. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study. Value Health 2005;8:178-90
31. Hoogendoorn M, Feenstra TL, Rutten-van Molken MP. Projections of future resource use and the costs of asthma and COPD in the Netherlands. Ned Tijdschr Geneeskd 2006;150:1243-50
32. Poos MJJC. Longkanker naar leeftijd en geslacht. [Lung cancer by age and gender]. In: Volksgezondheid Toekomst Verkenning, Nationaal Kompas Volksgezondheid. Bilthoven: RIVM; 2005
33. Trippoli S, Vaiani M, Lucioni C, et al. Quality of life and utility in patients with non-small cell lung cancer [Quality-of-life Study Group of the Master 2 Project in Pharmacoeconomics]. Pharmacoeconomics 2001;19:855-63
34. Slobbe LCJ, Kommer GJ, Smit JM, et al. Kosten van Ziekten in Nederland 2003. [Cost of illness in the Netherlands in 2003]. RIVM: Bilthoven; 2006. Available at: www.kostenvanziekten.nl (December, 2006)
35. Poos MJJC. Coronaire hartziekten: prevalentie, incidentie, ziekenhuisopnamen en sterfte naar leeftijd en geslacht. [Coronary heart disease: prevalence, incidence, hospitalizations and mortality by age and gender]. In: Volksgezondheid Toekomst Verkenning, Nationaal Kompas Volksgezondheid. Bilthoven: RIVM; 2006
36. Koek HL, van Leest LATM, W.M.M. V, et al. Hart- en vaatziekten in Nederland 2004, cijfers over leefstijl- en risicofactoren, ziekte en sterfte. [Cardiovascular disease in the Netherlands in 2004, data about lifestyle and risk factors, disease and mortality]. Den Haag: Nederlandse Hartstichting; 2004
37. Suryapranata H, Ottervanger JP, Nibbering E, et al. Long term outcome and cost-effectiveness of stenting versus balloon angioplasty for acute myocardial infarction. Heart 2001;85:667-71
38. Poos MJJC. Beroerte: prevalentie, incidentie, ziekenhuisopnamen en sterfte naar leeftijd en geslacht. [Stroke: prevalence, incidence, hospitalizations and mortality by age and gender]. In: Volksgezondheid Toekomst Verkenning, Nationaal Kompas Volksgezondheid. Bilthoven: RIVM; 2004
39. Jager-Geurts MH, Peters RJG, Van Dis SJ, et al. Hart- en vaatziekten in Nederland 2006, cijfers over ziekte en sterfte. [Cardiovascular disease in the Netherlands in 2006, data about disease and mortality]. Den Haag: Nederlandse Hartstichting; 2006
40. McNamara RL, Lima JA, Whelton PK, et al. Echocardiographic identification of cardiovascular sources of emboli to guide clinical management of stroke: a cost-effectiveness analysis. Ann Intern Med 1997;127:775-87
41. Struijs JN, van Genugten ML, Evers SM, et al. Future costs of stroke in the Netherlands: the impact of stroke services. Int J Technol Assess Health Care 2006;22:518-24
42. Poos MJJC. Astma: prevalentie, incidentie, ziekenhuisopnamen en sterfte naar leeftijd en geslacht. [Asthma: prevalence, incidence, hospitalizations and mortality by age and gender]. In: Volksgezondheid Toekomst Verkenning, Nationaal Kompas Volksgezondheid. Bilthoven: RIVM; 2006
43. Landelijke Medische Registratie (LMR). [National Medical Registration]. Utrecht: Prismant; 2003
44. Szende A, Svensson K, Stahl E, et al. Psychometric and utility-based measures of health status of asthmatic patients with different disease control level. Pharmacoeconomics 2004;22:537-47
45. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. J Am Med Assoc 2006;296:47-55
46. Kaper J. Smoking cessation treatment and its reimbursement. University of Maastricht, Maastricht. http://arno.unimaas.nl/show.cgi?fid=5377 [October, 2007]
47. Foulds J. Strategies for smoking cessation. Br Med Bull 1996;52:157-73
48. Feenstra TL, Van Baal PH, Hoogenveen RT, et al. Cost-effectiveness of interventions to reduce tobacco smoking in the Netherlands. An application of the RIVM Chronic Disease Model. Bilthoven: RIVM; 2006. http://www.rivm.nl/ bibliotheek/rapporten/260601003.pdf (March, 2007)
49. Anon. Pharmacotherapeutic compass. Health Care Insurance Board: Diemen; 2006
50. STIVORO. Roken, de harde feiten: Volwassen 2005. [Smoking facts, adults 2005]. Den Haag: STIVORO; 2005
51. Rodenburg-van Dieten HEM. Richtlijnen voor farmacoeconomisch onderzoek; evaluatie en actualisatie. [Guidelines for pharmaco-economic research; evaluation and update]. Diemen: College voor zorgverzekeringen; 2005
52. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000;17:479-500
53. Wetter DW, Cofta-Gunn L, Fouladi RT, et al. Late relapse/sustained abstinence among former smokers: a longitudinal study. Prev Med 2004;39:1156-63
54. Krall EA, Garvey AJ, Garcia RI. Smoking relapse after 2 years of abstinence: findings from the VA Normative Aging Study. Nicotine Tob Res 2002;4:95-100
55. Kaper J, Wagena EJ, van Schayck CP, et al. Encouraging smokers to quit: the cost effectiveness of reimbursing the costs of smoking cessation treatment. Pharmacoeconomics 2006;24:453-64
56. US Department of Health and Human Services. The health consequences of smoking: a report of the Surgeon General. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion. Office on Smoking and Health; 2004
57. Jacobs-van der Bruggen MAM, Welte RA, Koopmanschap MA, et al. Aan roken toe te schrijven productiviteitskosten voor Nederlandse werkgevers in 1999. [Smoking-related productivity costs for Dutch employers in 1999]. Bilthoven: RIVM; 2002
58. Barendregt JJ, Bonneux L, van der Maas PJ. The health care costs of smoking. New Engl J Med 1997;337:1052-7
59. Sloan FA, Ostermann J, Picone G. The price of smoking. MA: Massachusetts Institute of Technology; 2004
60. Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 1997;16:33-64
61. Nyman JA. Should the consumption of survivors be included as a cost in cost-utility analysis? Health Econ 2004;13:417-27
62. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998;13:397-409
63. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - modeling studies. Value Health 2003;6:9-17